After 1 year of biologic therapy, admissions requiring noninvasive ventilation among patients with COPD and type 2 ...
Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding ...
When breathing becomes a daily battle, even the simplest acts can feel exhausting. Now, a new study has found the key to ...
Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...
Receiving dupilumab for 52 weeks lowered the risk for severe exacerbations vs. placebo in adults with COPD and type 2 ...
High-dose fluticasone increases sputum bacterial load in severe COPD; ICS withdrawal is poorly tolerated, highlighting ...
Obstructive sleep apnoea (OSA) affects up to 1 billion people worldwide and is defined by repeated upper airway collapse during sleep, leading to intermittent hypoxaemia and disrupted sleep. Although ...
GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be ...
Cemiplimab (Libtayo; Regeneron Pharmaceuticals) has been approved as an adjuvant treatment for adult patients with cutaneous ...
The Guam Memorial Hospital Authority calculated 33 new fee items from March to July 2025 totaling $11,185.55. During its quarterly public hearing, GMHA said they released the fees for insurance ...
Due to chronic inflammation, those with COPD must learn to listen to what their bodies are telling them, writes columnist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback